Ads
related to: narcolepsy treatment sunosi- Get A Savings Card
You may pay as little as
$9 a month for SUNOSI.
- Cost Of SUNOSI
Learn about the affordability of
SUNOSI. See the savings program.
- Patient Brochure
View the patient brochure to
learn more about SUNOSI.
- Savings Card
Learn more about affordability
with our savings card program.
- Common Side Effects
Here's what you need to
know about possible side effects.
- Read The Dosing Info
Learn about the dosing
considerations of SUNOSI.
- Get A Savings Card
Search results
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Zacks via Yahoo Finance· 2 months agoData from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental...
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics’ AXSM shares have surged 118.4% in the past three months against the industry’s...
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Zacks via Yahoo Finance· 2 weeks agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of $1.00 per share for the first quarter of...
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome Therapeutics, Inc. AXSM incurred a loss of $1.03 per share (excluding intangible asset...
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
Zacks via Yahoo Finance· 2 months agoAxsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi...
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. AXSM incurred an adjusted loss of $1.28 per share in the fourth quarter of...
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
Zacks via Yahoo Finance· 10 months agoAxsome AXSM announced that the first patient has been dosed in the late-stage, label expansion study...
Axsome Therapeutics' Sunosi Improves Cognitive Function In Patients With Sleep Disorder
Benzinga via Yahoo Finance· 2 years agoAxsome Therapeutics Inc's (NASDAQ: AXSM) Sunosi met the primary endpoint in the SHARP study and...
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Zacks via Yahoo Finance· 1 month agoAlkermes plc ALKS announced positive top-line data from a phase Ib study evaluating its novel,...
Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.
Investor's Business Daily· 1 year agoAxsome Therapeutics and BioXcel Therapeutics issued divergent earnings reports Monday. BTAI stock...
Ad
related to: narcolepsy treatment sunosi
